Dnistrian A M, Schwartz M K, Katopodis N, Fracchia A A, Stock C C
Cancer. 1982 Nov 1;50(9):1815-9. doi: 10.1002/1097-0142(19821101)50:9<1815::aid-cncr2820500927>3.0.co;2-h.
The reliability of lipid-bound sialic acid (LSA) as a marker in breast cancer was evaluated in 78 normal subjects, 106 patients with benign breast disease, 64 patients with primary operable breast cancer, and 61 patients with recurrent metastatic breast cancer. LSA levels were determined before and after mastectomy and during chemotherapy in selected patients to determine the value of LSA in monitoring therapy and predicting response. LSA levels greater than 20 mg/dl were not seen in normal subjects but were present in patients with benign breast disease (13%), primary breast cancer (47%) and recurrent metastatic breast cancer (62%). LSA levels decreased after initiation of chemotherapy and remained low in patients clinically disease-free. Recurrences were associated with elevated LSA in patients failing chemotherapy or endocrine ablative surgery. LSA measurements appeared to be of limited value in the detection of breast cancer but serial measurements may be useful in assessing disease progression and identifying patients resistant to therapy.
在78名正常受试者、106名患有良性乳腺疾病的患者、64名患有原发性可手术乳腺癌的患者以及61名患有复发性转移性乳腺癌的患者中，评估了脂质结合唾液酸（LSA）作为乳腺癌标志物的可靠性。在选定患者的乳房切除术前、术后以及化疗期间测定LSA水平，以确定LSA在监测治疗和预测反应方面的价值。正常受试者中未发现LSA水平高于20mg/dl，但在患有良性乳腺疾病的患者（13%）、原发性乳腺癌患者（47%）和复发性转移性乳腺癌患者（62%）中存在。化疗开始后LSA水平下降，临床无疾病的患者LSA水平保持较低。化疗或内分泌消融手术失败的患者复发与LSA升高有关。LSA测量在乳腺癌检测中似乎价值有限，但连续测量可能有助于评估疾病进展和识别对治疗耐药的患者。
